Lack of mutations in the thyroid hormone receptor (TR) α and β genes but frequent hypermethylation of the TRβ gene in differentiated thyroid tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 12, 2007, Pages 4766-4770

  Joseph, Biju ^a   Ji, Meiju ^a   Liu, Dingxie ^a   Hou, Peng ^a   Xing, Michael Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA;

ALLELE; ARTICLE; CANCER CELL; CARCINOGENESIS; DNA METHYLATION; DNA SEQUENCE; GENE DISRUPTION; GENE MUTATION; GENE SILENCING; HETEROZYGOSITY LOSS; MUTATIONAL ANALYSIS; PAPILLOMA; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; THYROID ADENOMA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; TUMOR DIFFERENTIATION; ZYGOSITY;

EID: 36849072633     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0812     Document Type: Article

References (25)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648
2. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262
3. Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F 2005 Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol 70:461-467
4. Ciampi R, Nikiforov YE 2007 RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148:936-941
5. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688-4693
6. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199-10207
7. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161-1170
8. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA 2000 PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma [corrected]. Science [Erratum (2000) 289:1474] 25:1357-1360
9. Xing M 2007 Gene methylation in thyroid tumorigenesis. Endocrinology 148:943-953
10. Cheng SY 2003 Thyroid hormone receptor mutations in cancer. Mol Cell Endocrinol 213:23-30
11. Gonzalez-Sancho JM, Garcia V, Bonilla F, Munoz A 2003 Thyroid hormone receptors/THR genes in human cancer. Cancer Lett 192:121-132
12. Laudet V, Begue A, Henry-Duhhoit C, Joubel A, Martin P, Stehelin D, Saule S 1991 Genomic organization of the human thyroid hormone receptor ∞ (c-erbA-1) gene. Nucleic Acids Res 19:1105-1112
13. Escriva H, Delaunay F, Laudet V 2000 Ligand binding and nuclear receptor evolution. Bioessays 22:717-727
14. Yen PM 2003 Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab 14:327-333
15. Suzuki H, Willingham MC, Cheng SY 2002 Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12:963-969
16. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J 2002 Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87:1120-1128
17. Takano T, Miyauchi A, Yoshida H, Nakata Y, Kuma K, Amino N 2003 Expression of TRβ1 mRNAs with functionally impaired mutations is rare in thyroid papillary carcinoma. J Clin Endocrinol Metab 88:3447-3449
18. Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, Ladenson PW, Sidransky D 2003 Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 63:2316-2321
19. Adams M, Matthews C, Collingwood TN, Tone Y, Beck-Peccoz P, Chatterjee KK 1994 Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. J Clin Invest 94:506-515
20. Grebe S, McIver B, Hay ID, Wu PS-C, Maciel LMZ, Drabkin HA, Goellner JR, Grant CS, Jenkins RB, Eberhardt NL 1997 Frequent loss of heterozygosity on chromosome 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab 82:3684-3691
21. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, de la Chapelle A 1996 Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 56:3331-3337
22. Rocha AS, Marques R, Bento I, Soares R, Magalhaes J, de Castro IV, Soares P 2007 Thyroid hormone receptor β mutations in the 'hot-spot region' are rare events in thyroid carcinomas. J Endocrinol 192:83-86
23. Rodrigues-Serpa A, Catarino A, Soares J 2003 Loss of heterozygosity in follicular and papillary thyroid carcinomas. Cancer Genet Cytogenet 141:26-31
24. Wallin G, Bronnegard M, Grimelius L, McGuire J, Torring O 1992 Expression of the thyroid hormone receptor, the oncogenes c-myc and H-ras, and the 90 kD heat shock protein in normal, hyperplastic, and neoplastic human thyroid tissue. Thyroid 2:307-313
25. Bronnegard M, Torring O, Boos J, Sylven C, Marcus C, Wallin G 1994 Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic, and neoplastic human thyroid tissue. J Clin Endocrinol Metab 79:384-389